To better understand the pathophysiology of NUP98-NSD1, we developed a patient-derived xenograft (PDX) model by transplanting primary patient cells into immunodeficient mice and demonstrated that targeted inhibition of the driver oncogene NUP98-NSD1 provides a survival advantage in this type of AML. The gene discussed is NUP98; the disease is acute myeloid leukemia.